^
Association details:
| Biomarker: | HER-2 overexpression |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Trazimera (trastuzumab-qyyp) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
07/26/2018
Excerpt:
Trazimera should only be used in patients with metastatic gastric cancer (MGC) whose tumours have HER2 overexpression as defined by IHC2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result.
